Comparison of treatment outcomes of childhood Hodgkin lymphoma in two US centers and a center in Recife, Brazil
- 5 June 2007
- journal article
- research article
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 49 (2) , 139-144
- https://doi.org/10.1002/pbc.20883
Abstract
Background: Pediatric Hodgkin lymphoma (HL) has a cure rate of more than 80% in high‐income countries (HIC). However, more than 80% of the world's children live in low‐income countries (LIC), where the cure rate is often much lower.Procedure: We compared the outcome of HL of 371 patients treated at two pediatric oncology centers in the US to that of 62 patients treated at one center in Recife, Brazil (IMIP) to determine whether the same treatment strategy should be used in both high‐income and LIC. The logrank test was used to compare event‐free and overall survival.Results: The percentages of patients with unfavorable disease at each center were similar (P = 0.72). Patients with favorable disease at IMIP had estimated 5‐year survival rates comparable to those of the US centers (100% and 99%, respectively). Among patients with unfavorable disease, those treated at IMIP had a 5‐year event‐free survival (EFS) rate of 60%, compared to 78% at the US centers; (P = 0.08). The 5‐year survival estimate after relapse was 25% at IMIP versus 61% at the US centers (P = 0.08). The 5‐year overall survival for patients with unfavorable disease was 72% at IMIP versus 90% at the US centers (P = 0.01).Conclusions: Intensive frontline therapy should be considered for patients with unfavorable HL in LIC where the relapse rate is high and the salvage rate is low, provided that supportive care is adequate. Pediatr Blood Cancer 2007;49:139–144.Keywords
This publication has 16 references indexed in Scilit:
- Presalvage prostate‐specific antigen (PSA) and PSA doubling time as predictors of biochemical failure of salvage cryotherapy in patients with locally recurrent prostate cancer after radiotherapyCancer, 2006
- Risk-Adapted, Combined-Modality Therapy With VAMP/COP and Response-Based, Involved-Field Radiation for Unfavorable Pediatric Hodgkin's DiseaseJournal of Clinical Oncology, 2004
- Statement by members of the Ponte di Legno Group on the right of children to have full access to essential treatment for acute lymphoblastic leukemiaPediatric Blood & Cancer, 2004
- Establishment of a Pediatric Oncology Program and Outcomes of Childhood Acute Lymphoblastic Leukemia in a Resource-Poor AreaJAMA, 2004
- Malawi pilot study of Burkitt lymphoma treatmentMedical and Pediatric Oncology, 2003
- Childhood Hodgkin disease treated with COPP/ABV hybrid chemotherapy: A progress reportMedical and Pediatric Oncology, 2002
- Randomized Comparison of Low-Dose Involved-Field Radiotherapy and No Radiotherapy for Children With Hodgkin’s Disease Who Achieve a Complete Response to ChemotherapyJournal of Clinical Oncology, 2002
- VAMP and Low-Dose, Involved-Field Radiation for Children and Adolescents With Favorable, Early-Stage Hodgkin’s Disease: Results of a Prospective Clinical TrialJournal of Clinical Oncology, 2002
- Treatment of Unfavorable Childhood Hodgkin’s Disease With VEPA and Low-Dose, Involved-Field RadiationJournal of Clinical Oncology, 2002
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958